Last updated on June 2019

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Other Details:

Phase 1 dose escalation of MRTX849 to determine maximum tolerated dose.
Phase 1b expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 to recommend
Phase 2 regimens. Separate Phase 2 cohorts of patients stratified by histological diagnosis for evaluation of clinical activity of MRTX849.

MRTX849 will be administered orally in a continuous regimen.

Find a site near you

Start Over

Mirati Research Site

Located in: Orange, CA USA
  Connect »